Hypoparathyroidism historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 2: Line 2:
{{Hypoparathyroidism}}
{{Hypoparathyroidism}}


{{CMG}}; {{AE}}
{{CMG}}; {{AE}} {{Anmol}}


==Overview==
==Overview==

Revision as of 18:35, 18 September 2017

Hypoparathyroidism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoparathyroidism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoparathyroidism historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoparathyroidism historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoparathyroidism historical perspective

CDC on Hypoparathyroidism historical perspective

Hypoparathyroidism historical perspective in the news

Blogs on Hypoparathyroidism historical perspective

Directions to Hospitals Treating Hypoparathyroidism

Risk calculators and risk factors for Hypoparathyroidism historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

In 1909, William George MacCallum and Carl Voegtlin, demonstrated association between parathyroid gland, calcium, and tetany. In 1959, Howard Rasmussen and Lyman C. Craig at the Rockefeller Institute for Medical Research purified parathyroid hormone. In 1925, James Bertram Collip along with Douglous B Leitch treated tetany with the help of parathyroid extract. In 2015, Use of rhPTH (1–84) for the management of hypoparathyroidism is approved by the U.S. Food and Drug Administration (FDA).

Historical Perspective

Discovery

  • In 1852, Sir Richard Owen, Hunterian Professor and Conservator of the Museum in the Royal College of Surgeons of England, described parathyroids in rhinoceros.[1]
  • In 1880, Ivar Sandström, a Swedish anatomist, described parathyroids in human following 50 autopsies. He found two parathyroid glands bilaterally in 43 out of 50 autopsies.[2]
  • In 1909, William George MacCallum and Carl Voegtlin, demonstrated association between parathyroid gland, calcium, and tetany.[3]
  • In 1942, Albright et. al. first described the term pseudohypoparathyroidism. It is an example of Seabright-Bantam syndrome. In pseudohypoparathyroidism hypocalcemia and hyperphosphatemia is resistant to parathyroid hormone administration.[4]
  • In 1959, Howard Rasmussen and Lyman C. Craig at the Rockefeller Institute for Medical Research purified parathyroid hormone.[5] They also isolated the active polypeptide (parathormone B) from bovine parathyroid gland and gave its tentative formula in 1961.[6]

Landmark Events in the Development of Treatment Strategies

  • In 1925, James Bertram Collip along with Douglous B Leitch treated tetany with the help of parathyroid extract. They names the extract as Parathyrin.[7]
  • In 2015, Use of rhPTH (1–84) for the management of hypoparathyroidism is approved by the U.S. Food and Drug Administration (FDA).[8]

References

  1. Modarai B, Sawyer A, Ellis H (2004). "The glands of Owen". J R Soc Med. 97 (10): 494–5. doi:10.1258/jrsm.97.10.494. PMC 1079622. PMID 15459265.
  2. Johansson H (2015). "The Uppsala anatomist Ivar Sandström and the parathyroid gland". Ups. J. Med. Sci. 120 (2): 72–7. doi:10.3109/03009734.2015.1027426. PMC 4463479. PMID 25913489.
  3. Maccallum WG, Voegtlin C (1909). "ON THE RELATION OF TETANY TO THE PARATHYROID GLANDS AND TO CALCIUM METABOLISM". J. Exp. Med. 11 (1): 118–51. PMC 2124703. PMID 19867238.
  4. Albright F, Burnett CH, Smith PH, Parson (1942). "Pseudohypoparathyroidism- An example of 'Seabright-Bantam syndrome'". Endocrinology. 30: 922–32.
  5. Rasmussen, Howard; Craig, Lyman C. (1959). "PURIFICATION OF PARATHYROID HORMONE BY USE OF COUNTERCURRENT DISTRIBUTION". Journal of the American Chemical Society. 81 (18): 5003–5003. doi:10.1021/ja01527a066. ISSN 0002-7863.
  6. Rasmussen, Howard; Craig, Lyman C. (1961). "Isolation of a Parathyroid Polypeptide from Acetic Acid Extracts of Bovine Parathyroid Glands". {Journal of Biological Chemistry. 236 (4): 1083–1086.
  7. Collip JB, Leitch DB (1925). "A Case of Tetany treated with Parathyrin". Can Med Assoc J. 15 (1): 59–60. PMC 1707993. PMID 20315252.
  8. Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT (2016). "Management of Hypoparathyroidism: Present and Future" (PDF). J. Clin. Endocrinol. Metab. 101 (6): 2313–24. doi:10.1210/jc.2015-3910. PMC 5393596. PMID 26938200.

Template:WH Template:WS